| Consensus guidelines for the detection of immunogenic cell death O Kepp, L Senovilla, I Vitale, E Vacchelli, S Adjemian, P Agostinis, ... Oncoimmunology 3 (9), e955691, 2014 | 831 | 2014 |
| Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies ST Workenhe, KL Mossman Molecular Therapy 22 (2), 251-256, 2014 | 197 | 2014 |
| The fight between the teleost fish immune response and aquatic viruses ST Workenhe, ML Rise, MJT Kibenge, FSB Kibenge Molecular Immunology 47 (16), 2525-2536, 2010 | 162 | 2010 |
| Countermeasures against viral diseases of farmed fish FSB Kibenge, MG Godoy, M Fast, S Workenhe, MJT Kibenge Antiviral research 95 (3), 257-281, 2012 | 152 | 2012 |
| Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy ST Workenhe, G Simmons, JG Pol, BD Lichty, WP Halford, KL Mossman Molecular Therapy 22 (1), 123-131, 2014 | 124 | 2014 |
| Critical interactions between immunogenic cancer cell death, oncolytic viruses, and the immune system define the rational design of combination immunotherapies JP van Vloten, ST Workenhe, SK Wootton, KL Mossman, BW Bridle The Journal of Immunology 200 (2), 450-458, 2018 | 97 | 2018 |
| Infectious salmon anaemia virus replication and induction of alpha interferon in Atlantic salmon erythrocytes ST Workenhe, MJT Kibenge, GM Wright, DW Wadowska, DB Groman, ... Virology journal 5, 1-12, 2008 | 90 | 2008 |
| Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy ST Workenhe, JG Pol, BD Lichty, DT Cummings, KL Mossman Cancer immunology research 1 (5), 309-319, 2013 | 80 | 2013 |
| Infectious salmon anaemia virus (ISAV) isolates induce distinct gene expression responses in the Atlantic salmon (Salmo salar) macrophage/dendritic-like cell line TO, assessed … ST Workenhe, TS Hori, ML Rise, MJT Kibenge, FSB Kibenge Molecular immunology 46 (15), 2955-2974, 2009 | 78 | 2009 |
| Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors JG Pol, S Levesque, ST Workenhe, S Gujar, F Le Boeuf, DR Clements, ... Oncoimmunology 7 (12), e1503032, 2018 | 73 | 2018 |
| Structural and functional studies of an IRF-7-like gene from Atlantic salmon Ø Kileng, V Bergan, ST Workenhe, B Robertsen Developmental & Comparative Immunology 33 (1), 18-27, 2009 | 64 | 2009 |
| Cytokines in oncolytic virotherapy JG Pol, ST Workenhe, P Konda, S Gujar, G Kroemer Cytokine & Growth Factor Reviews 56, 4-27, 2020 | 48 | 2020 |
| De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitors ST Workenhe, A Nguyen, D Bakhshinyan, J Wei, DN Hare, KL MacNeill, ... Communications biology 3 (1), 645, 2020 | 38 | 2020 |
| The role of oncolytic virus immunotherapies to subvert cancer immune evasion ST Workenhe, ML Verschoor, KL Mossman Future Oncology 11 (4), 675-689, 2015 | 34 | 2015 |
| Pre-surgical neoadjuvant oncolytic virotherapy confers protection against rechallenge in a murine model of breast cancer NT Martin, DG Roy, ST Workenhe, DJM van Den Wollenberg, RC Hoeben, ... Scientific Reports 9 (1), 1865, 2019 | 32 | 2019 |
| Tumor-intrinsic determinants of immunogenic cell death modalities ST Workenhe, J Pol, G Kroemer Oncoimmunology 10 (1), 1893466, 2021 | 31 | 2021 |
| Demonstration of infectious salmon anaemia virus (ISAV) endocytosis in erythrocytes of Atlantic salmon ST Workenhe, DW Wadowska, GM Wright, MJT Kibenge, FSB Kibenge Virology journal 4, 1-5, 2007 | 31 | 2007 |
| Absolute quantitation of infectious salmon anaemia virus using different real-time reverse transcription PCR chemistries ST Workenhe, MJT Kibenge, T Iwamoto, FSB Kibenge Journal of Virological Methods 154 (1-2), 128-134, 2008 | 28 | 2008 |
| Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis C Zakaria, P Sean, HD Hoang, LP Leroux, M Watson, ST Workenhe, ... PLoS Pathogens 14 (8), e1007264, 2018 | 27 | 2018 |
| Genome-wide lentiviral shRNA screen identifies serine/arginine-rich splicing factor 2 as a determinant of oncolytic virus activity in breast cancer cells ST Workenhe, T Ketela, J Moffat, BP Cuddington, KL Mossman Oncogene 35 (19), 2465-2474, 2016 | 27 | 2016 |
Karen MossmanProfessor of Pathology and Molecular Medicine, McMaster UniversityVerified email at mcmaster.ca
